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Sex Med RIntroduction: Epidemiologic research in female sexual dysfunction (FSD) has gained momentum in recent years,
particularly in clinical populations and in menopausal women. However, sexual dysfunction also affects pre-
menopausal women in general populations. Previous literature reviews have been unable to quantify the burden
of FSD in general populations. This has been due in part to different deﬁnitions of dysfunction, heterogeneous
study design, and the wide variety of measurement tools used.
Aim: To provide a meta-analytical estimate of the prevalence of FSD in premenopausal women.
Methods: Observational studies that assessed the prevalence of FSD in premenopausal women were system-
atically sought in relevant databases (January 2000 through July 2014). Publications that reported the prevalence
rate for at least one domain of FSD were included. A meta-analysis of prevalence rates was performed and a meta-
regression was used to analyze factors of study design.
Main Outcome Measures: Estimated prevalence rates of FSD and its domains (hypoactive sexual desire dis-
order, sexual aversion disorder, female sexual arousal disorder, lubrication difﬁculties, female orgasmic disorder,
and pain disorders).
Results: After screening 9,292 results, 440 publications were retrieved for full-text review. Of these, 135 studies
were included in the systematic review. Ninety-ﬁve of these studies were assessed further in a meta-analysis.
There was substantial heterogeneity among studies. The prevalence of FSD in premenopausal women was
estimated to be 40.9% (95% CI ¼ 37.1e44.7, I2 ¼ 99.0%). Prevalence rates of individual sexual disorders
ranged from 20.6% (lubrication difﬁculties) to 28.2% (hypoactive sexual desire disorder). Further analyses
showed signiﬁcantly higher rates of FSD in studies in Africa, studies that used non-validated assessment tools,
and studies without pharmaceutical funding.
Conclusion: Prevalence estimates of FSD vary substantially. Nonetheless, results show that FSD is a signiﬁcant
public health problem that affects 41% of premenopausal women around the globe. More research and improved
standardization are needed in this ﬁeld.
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Sexual function is an essential component of life. For this
reason, sexual dysfunction can have a negative impact on the
well-being of an individual. Sexual dysfunctions are a heteroge-
neous group of disorders that are typically characterized by a
clinically signiﬁcant disturbance in a person’s ability to respond
sexually or to experience sexual pleasure, according to the
Diagnostic and Statistical Manual of Mental Disease, Fourth Edi-
tion, Text Revision (DSM-IV-TR).1 Sexual dysfunction in women
includes hypoactive sexual desire disorder, sexual aversion dis-
order, female sexual arousal disorder, female orgasmic disorder,1
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2 McCool et aland pain disorders.1 Female sexual dysfunction (FSD) is related
to age, progressive, and highly prevalent, affecting 30% to 50%
of women.2
Although still far behind research on male sexual dysfunction,
research on FSD has attracted more interest in the past few de-
cades.3,4 Several studies have examined the prevalence of sexual
dysfunction in women with cancer,5 diabetes,6 and depression.7
Older women also have been a major focus of research owing to
increased interest in therapies that might decrease menopausal
symptoms.8 However, sexual dysfunction is not limited to clin-
ical settings or to women going through menopause. It is an
important health issue that affects younger women in general
populations.
Several literature reviews have been performed in the past 30
years, yet none has been able to quantify the overall number of
premenopausal women who report sexual dysfunction.9-11 In
1986 Nathan9 performed an epidemiologic analysis of 22 studies
(1929e1981) that assessed sexual dysfunction in men and
women in the general population. In the 19 studies that included
women, prevalence rates for inhibited desire (in women) ranged
from 1% to 35% and from 5% to 15% for inhibited female
orgasm. No estimate could be given for inhibited sexual excite-
ment (or arousal) because none of the studies inquired about
adequate stimulation and the presence of lubrication problems.
The sexual pain disorders, vaginismus and dyspareunia, had not
been assessed in general populations until that point. In her
analysis, Nathan struggled not only with limited epidemiologic
data but also with a wide variety of tools that used heterogeneous
deﬁnitions for sexual dysfunction.
The 1990 critical review from Spector and Carey10
(1948e1990) identiﬁed 20 studies that measured FSD in
various populations of women (minimum age ¼ 11 years,
maximum age ¼ 85 years). Community samples indicated a
prevalence of 5% to 10% for inhibited female orgasm, yet no
stable estimates could be determined for female sexual arousal
disorder, vaginismus, or dyspareunia. Spector and Carey
encountered similar problems as Nathan did and encouraged
future researchers to use a common classiﬁcation system for
sexual dysfunction “so that professionals can better compare and
evaluate the literature using a common argot. (pg 406)”
In 2004, West et al11 performed a systematic literature review
(1966e2004) and identiﬁed 40 studies focusing on FSD (min-
imum age ¼ 18 years, maximum age ¼ 75 years). They found
rates of sexual dysfunction that ranged from 1% to 50% for
desire disorders, 4% to 48% for arousal disorders, 3% to 50% for
anorgasmia, and 1% to 75% for dyspareunia. Like Nathan9 and
Spector and Carey,10 West et al were unable to provide an overall
prevalence estimate for FSD owing to the different deﬁnitions of
dysfunction and the lack of standardized, valid assessment tools.
Currently, there is no global estimate of the prevalence of FSD
in general populations of premenopausal women. Currently, the
most frequently cited statistic for the prevalence of FSD stemsREV 5.4.0 DTD  SXMR47_proofrom a 1999 study published in the Journal of the American
Medical Association.12 The prevalence rate of generalized FSD
was estimated to be 43% in a U.S. population 18 to 59 years
old.13 However, to have a valid estimate of the global prevalence
of a particular disease or disorder, a single study of a single
population is not sufﬁcient.
A robust epidemiologic analysis of prevalence rates of FSD is
valuable not only for statistical purposes but also, more impor-
tantly, for its clinical relevance. Quantifying an illness is the ﬁrst
step in ﬁnding a possible cure for that illness, and this is true for
FSD.9 Establishing the prevalence of sexual dysfunction in pre-
menopausal and menopausal women allows practitioners and
administrators to use these data to determine the resources (eg,
more research, improved training, etc) needed to alleviate a given
disorder.10 Thus, the aim of this systematic review was to provide
a meta-analytical estimate of the prevalence of FSD in general
populations of premenopausal women and to examine the factors
that might affect these prevalence rates.METHODS
Protocol and Registration
The methods for this systematic review and meta-analysis were
developed according to recommendations from the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statements.14 This protocol has been registered with
the International Prospective Register of Systematic Reviews
(PROSPERO; CRD42014009526) and is available in published
form.15Search Strategy and Selection Criteria
Data for this review were identiﬁed by searches of Medline,
Embase, PsycINFO, Web of Science, and other relevant data-
bases using the terms sexual dysfunction, female, and epidemiology.
Searches were limited to studies of humans, to the English lan-
guage, and from January 1, 2000 until July 10, 2014. The search
was performed by an experienced medical research librarian
(H.K.). A list of search terms that were used can be requested
from the corresponding author. All titles and abstracts were
screened for their relevance (M.E.M.). If there was any uncer-
tainty about an abstract’s relevance at this stage, the article
remained included until the full text was reviewed. Articles
identiﬁed through hand searches were considered for inclusion
based on their titles.
A standard form was designed and used to evaluate the full-
text publications for inclusion (see Supplementary Material).
Two investigators (M.E.M. and A.Z.) independently assessed
each publication for eligibility and compared their results. If
there was a discrepancy in their assessment, a ﬁnal decision was
taken based on discussions with a third reviewer (C.A.). For
multiple publications based on a single study, the most current
and/or inclusive study was selected. A second hand search wasSex Med Rev 2016;-:1e16
f  15 April 2016  5:10 pm  ce
Female Sexual Dysfunction in Premenopausal Women 3performed (A.Z.) using the reference lists of all included
articles.
Cross-sectional, cohort, and case-control studies were eligible
for this systematic review. Validation studies, reviews, reports,
and commentaries were not included. Clinical populations or
populations of women who were surveyed for a particular disease
or illness were excluded. Studies that addressed FSD in infertile
women or couples and studies that examined spouses and part-
ners of men with erectile disorder also were excluded.
To be included, the study needed to report the prevalence of
FSD or at least one domain of FSD according to the DSM-IV-TR
(hypoactive sexual desire disorder, sexual aversion disorder, fe-
male sexual arousal disorder, female orgasmic disorder, or pain
disorders), because this would have been the relevant diagnostic
manual at the time of the studies (2000e2014).1 In the DSM-
IV-TR, female sexual arousal disorder was described entirely in
terms of genital indices of a sexual response, namely the
lubrication-swelling response.1,16 However, since its publication
in 2000, further evidence has been shown for differentiating
central or subjective arousal from peripheral or genital arousal (ie,
lubrication).17,18 In their validated assessment tool, the Female
Sexual Function Index (FSFI; 2000), Rosen et al19 distinguished
between measurements of subjective arousal and measurements
of lubrication and assessed these aspects separately. Contrary to
the DSM-IV-TR, the FSFI, which is widely used in population
studies around the world,20 used the term sexual arousal to refer
to a woman’s subjective arousal and the term lubrication to refer
to the genital indices of a sexual response.19 Owing to variation
in classiﬁcation and in measurement tools across studies, the
authors chose to include any study that reported on sexual arousal
and/or lubrication.
The research question focused on premenopausal women in
the general population (ie, women beyond menarche and before
menopause who were not pregnant or lactating). Any studies that
focused primarily on menopausal, postmenopausal, pregnant, or
lactating women were excluded. Because several epidemiologic
studies covered a broad age range of women, a numeric cutoff
was used for the studies that did not specify which women were
premenopausal. Based on a recent systematic review, the age at
onset of natural menopause (the time at which a woman’s
reproductive capacity ceases)21 is estimated at 48.7 years.22 Thus,
studies were included if (i) all women surveyed were premeno-
pausal, (ii) the age range of the participants was between
menarche and 49 years, or (iii) data on women no older than 49
years could be extracted from the entire population.Data Collection
Data were extracted from the included studies using an elec-
tronic data extraction form created in Access (Microsoft Corp,
Redmond, WA, USA). The extraction form was predesigned and
pilot tested (M.E.M. and M.A.T.). A pilot test was performed
with 20 randomly selected publications on the prevalence of
FSD. Based on the results of the pilot test, the form was revisedSex Med Rev 2016;-:1e16
REV 5.4.0 DTD  SXMR47_proof by the investigators. If information necessary for the
meta-analysis was not contained within the article, the corre-
sponding author and/or coauthors were contacted personally. All
authors were contacted in September 2014 and were reminded, if
necessary. Where no reply was received or data were no longer
accessible, the investigators listed the article in the summary table
but did not include the study in the meta-analysis. After all data
were extracted from the included publications (M.E.M., A.Z.,
and M.A.T.), the data were examined and veriﬁed by a second
author (M.E.M., A.Z., and M.A.T.). Discrepancies in data entry
were documented, discussed, and revised accordingly.Classiﬁcation of Sexual Disorders
For the data collection process, prevalence rates were extracted
for FSD in general (eg, fulﬁlling a cutoff in the respective study)
and any of its domains: hypoactive sexual desire disorder, sexual
aversion disorder, female sexual arousal disorder, lubrication
difﬁculties, female orgasmic disorder, and pain disorders.1 Au-
thors of previous systematic analyses were confronted with dif-
ferences in terminology across studies and, in the end, used the
term female sexual dysfunction to describe any self-reported sexual
difﬁculty, regardless of duration, persistence, or level of personal
distress.9-11 Although the inclusion of personal distress has been
shown to yield lower prevalence rates of FSD in population
studies,23-25 very few previous studies included the criterion of
personal distress in their assessment of the prevalence of sexual
dysfunction.26 To provide a full scope of international prevalence
rates, the authors of this systematic literature review considered
all studies for inclusion, regardless of the duration of sexual
difﬁculties or the assessment of persistence or of personal distress.
Furthermore, solely for consistency purposes with the literature
in the observed timeframe, the authors used the term sexual
dysfunction for this systematic review.Methodologic Quality Assessment
Methodologic quality was assessed for all studies included in
the meta-analysis using a checklist from Prins et al.27 Using the
quality criteria, risk of bias was assessed for setting and dates of
study, eligibility criteria, sampling methods, participation rate,
description of participants, description of classiﬁcation of sexual
dysfunction, validation of assessment tool, and sources of fund-
ing for each study. Each study was assessed independently by two
investigators (M.E.M. and A.Z.). In case of disagreement,
consensus was reached through discussions with the senior
researcher of this study (C.A.).Statistical Analyses
A meta-analysis of the prevalence rates of FSD was performed
for overall FSD and for each domain using a quality effects model
(M.E.M.) and a random effects model (C.R.).28,29 Further sta-
tistical analyses were performed by an experienced epidemiologist
(C.R.). Cochran Q and I2 statistics were used to test for het-
erogeneity of the studies.30 Publication bias was examined using15 April 2016  5:10 pm  ce
4 McCool et althe Begg rank correlation test31 and the Egger correlation test.32
Sensitivity analyses were performed by dropping one study at a
time. A univariate meta-regression analysis33 was performed for
all six outcomes (FSD and ﬁve domains) and the following fac-
tors: region of the world, type of sexual regime,34 method of data
collection, sampling method, validation of assessment tool,
reporting period of assessment tool, inclusion criteria on sexual
activity, and pharmaceutical funding. Furthermore, the preva-
lence rates were correlated with the Gender Inequality Index to
determine whether there was a relation between the prevalence of
FSD and the level of gender inequality in a country.35 Statistical
analyses were performed using MetaXL. Meta-regressions were
performed using STATA 12.0 (StataCorp, College Station, TX,
USA).RESULTS
Characteristics of Studies
Of the 19,442 citations retrieved through electronic and other
references searches, 10,150 duplicates were excluded, leaving
9,292 titles and abstracts to be screened. Based on the title and/
or abstract, 8,852 citations were excluded. The full texts of 440
publications were evaluated. In the end, 135 publications ful-
ﬁlled all inclusion criteria.23-26,36-166 Figure 1 presents a
PRISMA ﬂowchart with reasons for exclusion. Sixty-seven re-
searchers were contacted for additional information for the meta-
analysis; 37 of 67 responded (55%) and/or supplied additional
data. The smallest population was 100 and the largest was
84,644. The mean study size was 2,420 participants and the
median was 853 participants.
Table 1 lists the general characteristics of the included studies.
Nearly all publications described cross-sectional studies. The
number of premenopausal women in these studies was generally
smaller than 2,000, with only three very large studies with more
than 10,000 premenopausal women. A third of studies took
place in European countries, followed by regions in the non-
European West167 (United States, Canada, South Africa, New
Zealand, and Australia) and Asia. Seventy studies (51.9%) used
paper questionnaires to collect data on reported sexual dysfunc-
tion. The FSFI from Rosen et al19 was the most frequently used
measurement tool (43 of 135, 31.9%). Thirty-six percent of
studies used measurement tools with unclear validation or no
validation.
Supplementary Table 1 lists speciﬁc characteristics of all
studies in the systematic review (N ¼ 135). Forty studies could
not be included in the quantitative analyses owing to insufﬁcient
data on participants and/or prevalence rates. Therefore, the meta-
analysis entailed 95 studies, comprising 215,740 participants.
The prevalence of FSD was reported in 53 studies. In terms of
the domains, the prevalence of hypoactive sexual desire disorder
was reported in 62 studies, sexual aversion disorder in 5 studies,
female sexual arousal disorder in 39 studies, lubrication difﬁ-
culties in 36 studies, female orgasmic disorder in 53 studies, andREV 5.4.0 DTD  SXMR47_proopain disorders in 65 studies. Because the vast majority of studies
did not include personal distress in their assessment of prevalence
(90%, n ¼ 85), the authors used the prevalence rates of sexual
dysfunction without personal distress.Study Risk of Bias
All studies included in the meta-analysis (n ¼ 95) were
assessed for their methodologic quality. The risk of bias for these
studies is presented in Figure 2. Of the 95 studies, only 2 (1%)
were judged as “low risk” on all risks of bias considered. The
prevalence rates were judged as reproducible in 77% of the
studies. In 37 studies (39%), the population observed was
randomly selected or considered representative of the larger
population. Fifty-nine studies (62%) used validated measure-
ment tools, and 63 studies (66%) speciﬁed the reporting period
of the measurement tool. However, 65 studies had a low
response rate or did not provide sufﬁcient information about the
population of non-responders.Meta-Analysis and Meta-Regression
Prevalence rates of FSD varied considerably among studies in
the quantitative analyses. Wide ranges of prevalence were present
in each domain of sexual dysfunction (hypoactive desire disorder,
6%e70%; sexual aversion disorder, 5%e24%; sexual arousal
disorder, 1%e60%; lubrication difﬁculties, 1%e53%; female
orgasmic disorder, 8%e72%; pain disorders, 1%e72%). A
meta-analysis was performed for FSD and for each domain of
FSD except for sexual aversion disorder, because there were not
sufﬁcient data for performing further stratiﬁcation.
Table 2 presents the meta-analytical prevalence rates for FSD
and its domains. The prevalence of FSD in premenopausal
women was estimated to be 40.9% (95% CI ¼ 37.1e44.7,
I2 ¼ 99.0%). The quality effects model yielded a similar esti-
mate of 40.4% (95% CI ¼ 33.3e47.0, I2 ¼ 99.1%). Preva-
lence estimates varied in the speciﬁc domains of FSD (random
effects model): 28.2% reported hypoactive sexual desire disor-
der (95% CI ¼ 24.1e32.5, I2 ¼ 99.5%), 22.6% reported
sexual arousal disorder (95% CI ¼ 18.8e26.8, I2 ¼ 99.2%),
20.6% reported lubrication difﬁculties (95% CI ¼ 16.9e24.6,
I2 ¼ 99.2%), 25.7% reported female orgasmic disorder (95%
CI ¼ 22.6e29.0, I2 ¼ 99.1%), and 20.8% reported pain
disorders (95% CI ¼ 18.3e23.5, I2 ¼ 99.2%). Heterogeneity
was high (I2 < 95%) in all estimates; none of the factors
analyzed could decrease heterogeneity substantially (I2  50%)
for any outcome.
Further subgroup analyses showed signiﬁcantly higher
prevalence rates of FSD in Africa and the lowest rates in the non-
European West. Studies performed in countries with gender-
equal sexual regimes had signiﬁcantly lower rates of lubrication
difﬁculties, female orgasmic disorder, and pain disorders. This
was supported by the correlation of prevalence rates with the
Gender Inequality Index (Table 2). In all domains, there was a
positive correlation, but a signiﬁcant, positive correlation wasSex Med Rev 2016;-:1e16
f  15 April 2016  5:10 pm  ce
135  Studies included in systematic 
review 
19,366 Records identified through 
database searching 
76 Additional records identified   
through other sources 
10,150 Duplicate records removed 
9,292 Records screened by title 
and abstract review 
8,852 Records excluded on screening of titles and 
abstracts using general criteria 
  440 Full text articles assessed 
for eligibility  
267  Articles excluded based on full text review using 
inclusion criteria 
53  Less than 100 participants 
40  Validation study 
87  Review, report, conference abstract, book 
26  No DSM domain of FSD reported 
35  DSM domain but not a prevalence study 
 8  Women diagnosed with FSD already 
 4  All women over 49 or all in menopause 
 1  Not women, wrong population 
 5  Clinical population 
 6  Model of sexual response cycle 
 2  Full text not accessible in English 
183  Studies fulfilled inclusion 
criteria 
95  Studies included in meta-
analyses 
48 Subset population from included 
study 
10  Additional articles 
from reference lists 
40 Absolute data for meta-analyses 
not available/provided by author 
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses ﬂowchart showing the number of citations retrieved from
a systematic literature search in multiple databases. DSM ¼ Diagnostic and Statistical Manual and Mental Disorders; FSD ¼ female sexual
dysfunction.
Female Sexual Dysfunction in Premenopausal Women 5established in FSD, particularly female orgasmic disorder and
pain disorders. Higher rates of sexual dysfunction were reported
in studies that used interviews and questionnaires together to
collect data. Random sampling and sampling from convenience
populations in outpatient settings (convenience clinical) showed
prevalence rates of 41%, but populations in the subgroupSex Med Rev 2016;-:1e16
REV 5.4.0 DTD  SXMR47_proof “convenience clinical” generally reported higher rates of sexual
dysfunction in the individual domains. The validity of the
assessment tool was examined, resulting in signiﬁcantly higher
prevalence rates in studies using non-validated tools and signif-
icantly lower rates in studies using validated tools. A further
subgroup analysis tested the hypothesis that the widely used,15 April 2016  5:10 pm  ce
Table 1. Characteristics of included studies (N ¼ 135)
Categorical variable n (%)
Study design
Cross-sectional 134 (99.3)
Cohort 1 (0.07)
Sizes of population: premenopausal women*
00e499 55 (47.4)
500e1,999 44 (37.9)
2,000e9,999 14 (12.1)
10,000e84,644 3 (2.6)
Region
Europe 45 (33.3)
Non-European West† 31 (23.0)
Asia 23 (17.0)
Central and South America 12 (8.9)
Africa 11 (8.1)
Middle East 10 (7.4)
Global 3 (2.2)
Method of data collection
Paper questionnaire 70 (51.9)
Interview and questionnaire 23 (17.0)
Face-to-face interview 17 (12.6)
Online survey 14 (10.4)
Telephone interview 9 (6.7)
Computer-assisted interview 2 (1.5)
Validation of assessment tool
Yes 86 (63.7)
No or unclear 49 (36.3)
Sampling method
Convenience clinical‡ 52 (38.5)
Random 50 (37.0)
Convenience community 32 (23.7)
Not clearly described 1 (0.7)
Pharmaceutical funding
No 88 (65.2)
Yes 18 (13.3)
Funding not reported 29 (21.5)
*N ¼ 116 studies; absolute numbers were missing for 19 studies.
†United States, Canada, South Africa, New Zealand, and Australia.
‡Women who were recruited in non-emergency clinical settings such
as obstetric and gynecologic waiting rooms.
6 McCool et alvalidated FSFI might yield different results from other validated
assessment tools and non-validated assessment tools. No clear
trend was apparent through this analysis. For reporting period,
assessment tools that inquired about symptoms in the past
month showed signiﬁcantly lower prevalence rates, whereas
studies with reporting periods of 2 to 12 months showed
signiﬁcantly higher rates. Studies that permitted only sexually
active women to participate showed generally higher prevalence
rates of sexual dysfunction compared with studies that did not
exclude women based on their current sexual activity. Prevalence
rates in studies with pharmaceutical funding were lower in all
domains—in some cases, signiﬁcantly lower.REV 5.4.0 DTD  SXMR47_prooNo evidence for publication bias could be indicated through
the Begg rank correlation test and Egger correlation test. Results
from the sensitivity analysis showed no effect by a single study.DISCUSSION
Prevalence Rates and Heterogeneity of Studies
In light of previous systematic reviews, it is clear that epide-
miologic research in FSD has increased substantially during the
past few years.9-11,168 The systematic literature review
(2000e2014) entailed 135 international studies, 95 of which
were included in the meta-analysis. This review far exceeds the
previous systematic review from West et al11 (1966e2004),
which entailed 40 studies in general populations of women.
Considering that peer-reviewed publications on FSD only began
to increase in approximately 2001,4 previous systematic reviews
could not provide the breadth and quantity of studies that this
review has been able to achieve.
Furthermore, this is the ﬁrst systematic review to provide an
estimate for FSD and the individual domains, because previous
systematic reviews could only provide broad ranges for the
prevalence of FSD. The meta-analytical estimate of international
prevalence studies indicates that 41% of premenopausal women
report sexual dysfunction. The prevalence of the individual dis-
orders of sexual dysfunction in premenopausal women ranges
from 21% to 28% (hypoactive sexual desire disorder, 28%; fe-
male sexual arousal disorder, 23%; lubrication difﬁculties, 21%;
female orgasmic disorder, 26%; pain disorders, 21%). These
results are in line with those of Laumann et al’s13 frequently cited
study, which estimated that 43% of women 18 to 59 years old
report sexual dysfunction. The estimated prevalence rates for the
various sexual disorders also were close to the ranges determined
by Laumann et al for women 18 to 49 years old: 30% to 32%
lacked interest in sex, 18% to 21% had lubrication difﬁculties,
22% to 28% could not achieve orgasm, and 13% to 21%
experienced pain during intercourse.
Substantial heterogeneity in population studies (eg, study
design, classiﬁcations of disorder, assessment tools, reporting
period, cutoffs, funding, etc) hindered authors of previous sys-
tematic reviews on FSD from establishing a prevalence esti-
mate.9-11 Meta-analyses provide a tool by which prevalence rates
can be quantiﬁed, yet heterogeneity is the main challenge in
these types of analyses.28 An I2 greater than 95% is not un-
common in meta-analytical estimates of prevalence rates.28
Subgroup analyses can provide possible explanations for the
heterogeneous results, as can weighing the studies according to
their quality (quality effects model). Thus, in addition to using
stratiﬁcation by subgroups, quality effects, and random effects
methods, the authors performed multiple tests for biases
including a risk of bias evaluation, correlation tests for publica-
tion bias, and sensitivity analyses. The methodologic assessment
indicates that a risk of bias might be present in several studies
owing to the non-representativeness of the populations. ThisSex Med Rev 2016;-:1e16
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Sources of funding acknowledged
Reported prevalence rates are reproducible
Reporting period specified in measurement tool
Measurement tool validated
Response rate >70% / information on non-responders
Random sample or representative population
Reasons for eligibility provided
Study period specified
Low risk
High risk
Figure 2. Risk of bias of included studies (n ¼ 95) Studies identiﬁed as “low risk” provided the necessary information to fulﬁll a speciﬁc
quality criterion. Studies identiﬁed as “high risk” did not provide sufﬁcient information to make a conclusion or did not fulﬁll the speciﬁc
quality criterion.
Female Sexual Dysfunction in Premenopausal Women 7underlines the need for improved population sampling to avoid
non-response biases and to compensate for the probability of
selection biases among subgroups.
Analysis of Factors
Worldwide, African studies reported signiﬁcantly higher rates
of FSD, whereas lower rates of sexual dysfunction were found in
Europe and the non-European West. Several countries in these
regions are considered to have gender-equal sexual regimes:
Austria, Belgium, France, Germany, Spain, Sweden, the United
Kingdom, Mexico, Australia, Canada, New Zealand, South Af-
rica, and the United States. In gender-equal sexual regimes,
prevalence estimates often were signiﬁcantly lower than in Asian
countries (China, Japan, and Thailand) and countries with male-
centered sexual regimes (Egypt, Italy, Morocco, Brazil, Malaysia,
and Turkey).34 Particularly in male-dominated cultures, where
sex might be viewed only as a method for procreation, women’s
sexual needs and pleasure are suppressed.100 Extreme cases of this
can be seen in African studies in which factors such as female
genital mutilation, polygamy, and rape by the partner were sig-
niﬁcant risk factors for FSD.69,75,121 High rates of FSD also were
found in Asian countries, as seen in subgroups “region” and
“sexual regime.” In these cultures, a different mechanism is at
work. Women who do not conform to traditional female roles
can experience greater difﬁculties.100 Higher education leads to
increased awareness of sexual needs and rights; thus, highly
educated women in Asia tend to feel more disappointment with
sexual relationships, which can lead to poor sexual func-
tioning.63,142 A correlation could be seen between the Gender
Inequality Index and prevalence rates (Table 2). For FSD, female
orgasmic disorder and pain disorders, a signiﬁcant positive cor-
relation was found between increasing gender inequality scores
(country scores of 0e1, with 1 being the greatest inequality) andSex Med Rev 2016;-:1e16
REV 5.4.0 DTD  SXMR47_proof increasing prevalence rates in a country. However, this correla-
tion was not evident with hypoactive sexual desire disorder; in
fact, prevalence rates of desire disorder were comparatively high
in gender-equal sexual regimes and in Europe and the non-
European West. In egalitarian societies such as these, correlates
such as full-time employment and housework imbalance with a
partner have been shown to be predictors of low sexual interest or
decreased sexual desire in women.137,152 Although it is not
possible to draw conclusions about the causal association of
gender (in)equality with sexual dysfunction, global studies have
found that sexual functioning, emotional pleasure, and physical
pleasure are rated higher in countries with greater gender
equality; this holds true for women’s and for men’s sexual well-
being.34
Study design was another major focus of this systematic re-
view. Similarly to previous systematic reviews, many assessment
tools were used to measure FSD; 49 of 135 (36%) had unclear
validity. The validated FSFI from Rosen et al19 was the most
frequently used assessment tool, yet even studies using the FSFI
applied various and/or non-validated cutoffs such as median
values or lowest quartile. Subgroup analyses did not show clear
differences between validated and non-validated instruments or
greater precision with the use of the FSFI, as seen in the wide
CIs. Thus, the large span in prevalence rates across studies might
not reﬂect real differences, but might be due to the different tools
and cutoffs that were used.169 Furthermore, there was great
variation in the reporting period. The FSFI asked about any
symptoms in the past month, whereas other studies queried
about symptoms in the past 3 months, 6 months, 12 months, or
ever. Hayes et al170 documented that even very minor differences
in the reporting period have an impact on prevalence rates.
Higher rates of sexual dysfunction were reported in studies that
used interviews and questionnaires together to collect data.15 April 2016  5:10 pm  ce
Table 2. Prevalence estimates of FSD by factors of study design (n ¼ 95)
Factors
Studies,
n
FSD, %
(95% CI)
Desire, %
(95% CI)
Arousal, %
(95% CI)
Lubrication, %
(95% CI)
Orgasm, %
(95% CI)
Pain, %
(95% CI)
Total (QE) 95* 40.4 (33.9e47.0) 26.4 (20.0e33.3) 15.4 (9.9e21.8) 16.3 (11.6e21.6) 20.9 (16.1e26.1) 14.4 (7.3e23.4)
Total (RE) 95* 40.9 (37.1e44.7) 28.2 (24.1e32.5) 22.6 (18.8e26.8) 20.6 (16.9e24.6) 25.7 (22.6e29.0) 20.8 (18.3e23.5)
Meta-regression GII
score slope (SE)
93 1.56 (0.65) 0.40 (0.71) 1.55 (0.910) 0.96 (0.95) 1.42 (0.55) 1.93 (0.59)
P value .020 .577 .094 .320 0012 .002
Region
Europe 36 39.1 (28.8e49.8) 27.0 (20.2e34.5) 16.3 (12.8e20.0)† 21.4 (17.5e25.5) 16.9 (12.8e21.4) 39.1 (28.8e49.8)
Non-European West 18 32.1 (21.1e44.2) 27.9 (18.9e37.9) 15.5 (8.8e23.6) 16.5 (8.4e26.7) 17.1 (10.1e25.5) 13.1 (8.6e18.3)
Asia 17 40.2 (31.4e49.4) 26.1 (20.6e32.1) 32.7 (25.8e40.0) 26.5 (17.9e36.0) 27.5 (19.5e36.3) 22.1 (16.7e28.0)
Central and South
America
10 45.5 (30.2e61.2) 28.6 (14.8e44.7) 34.6 (11.8e61.3) 45.5 (30.2e61.2) 27.1 (12.9e43.9) 26.6 (18.0e36.2)
Africa 6 61.7 (48.6e74.0)† 26.2 (01.2e62.9) 21.2 (01.2e51.9) - 52.6 (39.1e65.9)† 31.6 (16.5e48.8)
Middle East 8 47.0 (36.5e57.7) 38.8 (16.2e63.9) 32.5 (16.8e50.3) 25.4 (13.6e39.4) 29.9 (23.3e36.9) 35.3 (23.9e47.6)†
Type of sexual regime
Gender equal 37 34.7 (28.1e41.7) 24.8 (18.6e31.4) 11.0 (08.1e14.3) 13.5 (09.1e18.6)† 16.8 (13.5e20.5)† 12.1 (08.6e16.1)†
Asian 9 49.8 (37.0e62.7) 22.1 (16.8e27.9) 27.4 (23.3e31.7)† 25.4 (14.8e37.6) 25.4 (15.1e37.4) 16.8 (09.2e26.0)
Male centered 15 34.6 (26.3e43.3) 36.0 (21.4e51.9) 39.3 (32.2e46.7)† 37.2 (29.7e45.1)† 31.6 (22.7e41.3) 35.0 (30.0e40.2)†
Method of data collection
Paper questionnaire 51 37.3 (30.7e44.1) 26.2 (20.5e32.2) 24.0 (18.5e30.0) 21.7 (15.1e29.0) 24.6 (19.1e30.6) 22.0 (17.2e27.2)
Interview and
questionnaire
16 53.2 (46.1e60.3)† 38.0 (31.4e44.8) 24.2 (13.5e36.7) 23.7 (12.9e36.5) 36.0 (27.3e45.2)† 26.0 (18.9e33.9)
Face-to-face
interview
9 43.5 (37.3e49.8) 25.1 (16.5e34.8) 22.9 (09.4e39.8) 17.1 (11.1e24.2) 24.8 (17.7e32.7) 22.6 (17.2e28.4)
Online survey 10 37.3 (31.6e43.2) 25.5 (16.1e36.3) 16.5 (07.4e28.2) 16.3 (00.0e43.9) 21.0 (16.1e26.5) 12.7 (04.8e23.5)
Telephone interview 7 26.0 (03.4e57.2) 33.9 (12.1e59.6) 10.6 (8.5e13.1) 18.5 (9.5e29.5) 14.5 (5.2e27.1) 8.2 (1.5e18.6)
Computer-assisted
interview
2 - - - - 18.7 (1.0e46.7) -
Sampling method
Random 33 41.3 (33.8e48.9) 27.7 (20.8e35.1) 14.0 (10.2e18.4) 16.9 (12.3e22.0) 21.7 (17.0e26.8) 15.5 (12.5e18.7)†
Convenience clinical 37 41.2 (34.9e47.6) 32.2 (24.4e40.6) 29.5 (23.5e35.9) 23.0 (17.7e28.7) 29.6 (25.4e33.9) 27.0 (22.5e31.6)†
Convenience
community
25 39.6 (31.8e47.7) 23.1 (18.4e28.2) 19.2 (11.1e29.0) 21.1 (05.5e42.1) 23.9 (18.2e30.2) 17.2 (09.6e26.2)
Validation of assessment tool
Yes 62 37.3 (33.3e41.3)† 26.6 (21.9e31.5) 22.7 (18.3e27.4) 22.1 (17.2e27.4) 23.8 (20.1e27.6) 21.3 (16.9e26.0)
No or unclear 33 54.7 (46.6e62.7)† 31.3 (23.4e39.7) 22.3 (13.9e31.9) 16.3 (11.0e22.3) 29.9 (25.0e35.0) 20.1 (16.8e23.7)
Assessment tool
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Table 2. Continued
Factors
Studies,
n
FSD, %
(95% CI)
Desire, %
(95% CI)
Arousal, %
(95% CI)
Lubrication, %
(95% CI)
Orgasm, %
(95% CI)
Pain, %
(95% CI)
FSFI 31 36.3 (30.7e42.2) 31.3 (20.8e42.9) 27.0 (19.1e35.6) 26.5 (18.2e35.6)† 28.3 (21.5e35.7) 24.9 (17.5e33.2)
Other validated tool 31 38.9 (32.4e45.6) 21.8 (17.5e26.4) 14.6 (11.6e17.9) 14.3 (10.3e18.7) 18.4 (15.1e22.0) 18.0 (13.0e23.7)
Non-validated tool 33 54.7 (46.6e62.7)† 31.3 (23.4e39.7) 22.3 (13.9e31.9) 16.3 (11.0e22.3) 29.9 (25.0e35.0) 20.1 (16.8e23.7)
Reporting period
Past month 40 34.9 (29.4e40.6)† 29.9 (20.7e39.9) 25.7 (18.7e33.3) 25.4 (18.1e33.3) 26.9 (20.7e33.6) 23.2 (16.6e30.5)
Past 2e12 mo 26 50.0 (46.1e53.9)† 28.8 (21.8e36.4) 18.4 (09.5e29.3) 16.2 (12.2e20.5) 23.3 (19.4e27.4) 17.3 (13.8e21.2)
Not speciﬁed 29 46.9 (37.6e56.3) 24.7 (19.3e30.5) 19.3 (14.2e25.1) 13.1 (09.4e17.2) 27.1 (19.8e35.0) 22.0 (17.0e27.5)
Inclusion criteria
Current sexual
activity not
speciﬁed
34 36.6 (30.3e43.1) 23.5 (17.6e30.0) 15.7 (11.8e19.9) 18.9 (13.4e25.0) 21.9 (17.3e26.8) 15.3 (11.3e19.9)†
Sexually active or
only married
women
61 41.5 (36.9e46.2) 31.2 (26.1e36.6) 25.9 (20.1e32.3) 21.5 (16.2e27.3) 27.6 (23.5e31.9) 23.7 (20.2e27.3)†
Pharmaceutical funding
No 58 43.2 (38.5e48.0) 33.6 (26.7e40.8)† 25.1 (19.1e31.6) 21.0 (16.4e25.9) 27.9 (23.5e32.5) 43.2 (38.5e48.0)
Yes 17 32.4 (22.1e43.7) 18.0 (12.6e24.2)† 10.1 (9.6e10.6) 18.7 (10.5e28.6) 16.2 (10.8e22.3)† 14.8 (8.3e22.6)
Not reported 20 40.3 (33.2e47.6) 25.7 (20.0e31.9) 20.8 (13.3e29.4) 20.1 (14.2e26.7) 26.0 (20.4e31.9) 18.6 (12.1e26.1)
FSD ¼ female sexual dysfunction; FSFI ¼ Female Sexual Function Index; GII ¼ Gender Inequality Index; QE ¼ quality effects; RE ¼ random effects; SE ¼ standard error.
*Number of studies included in analysis for each domain: FSD, n ¼ 53; desire, n ¼ 62; arousal, n ¼ 39; lubrication, n ¼ 36; orgasm, n ¼ 53; pain, n ¼ 65.
†P < .05.
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10 McCool et alHowever, the 9 of 16 studies in this subset were performed in the
Middle East and Africa and had prevalence rates as high as
76.2%.
Approximately two-thirds of studies in the meta-analysis
required women to have been sexually active in the past year.
Excluding women based on sexual activity could create a bias in
that these non-sexually active women might not engage in in-
tercourse because of their sexual disorder.110 Furthermore, some
studies in Middle Eastern and African countries and India only
allowed married women to participate. However, recent studies
in these countries have shown that the restrictions surrounding
marriage are loosening and women’s sexual freedom is
increasing.171-173 Thus, studies including only married women
might not clearly represent women’s sexual health in the general
population.
The ﬁnal factor that was assessed in this meta-analysis was
the impact of pharmaceutical funding on prevalence rates,
because it has been shown that industry-sponsored research
tends to yield pro-industry conclusions.174 In 2003, as research
on women’s sexual health was beginning to gain momentum,
the article “The making of a disease: female sexual dysfunc-
tion” by Moynihan12 accused pharmaceutical companies and
clinicians and researchers of fabricating an illness. However,
this analysis clearly showed that studies with pharmaceutical
funding had consistently lower prevalence rates than those not
funded by pharmaceutical companies or those studies that did
not report funding sources. The studies in this subset were
primarily from Europe and the non-European West, which
generally had lower—but not necessarily signiﬁcantly
lower—prevalence rates. Studies funded by pharmaceutical
companies used validated questionnaires 70% of the time, as
did those not funded by pharmaceutical companies (funding
not reported 45% of the time). Pharmaceutically funded
studies used random sampling methods more often than did
those without funding or without reported funding (53% vs
36% and 15%, respectively). At closer examination of preva-
lence rates of hypoactive sexual desire disorder and orgasmic
disorder, which were signiﬁcantly lower, studies funded by
pharmaceutical companies achieved larger numbers of partici-
pants per study. Furthermore, these studies had higher study
quality and fewer biases compared with studies without phar-
maceutical funding or without reported funding. Thus, the
results of this analysis suggest that the prevalence rates pro-
vided through studies with pharmaceutical funding might be
more robust than those without pharmaceutical funding.Limitations of Included Studies
Although Spector and Carey10 urged researchers to ﬁnd a
common classiﬁcation system for sexual dysfunction, classiﬁca-
tion of FSD remains problematic.12,175,176 Basic terminology
proved to be inconsistent across publications. The terms sexual
difﬁculties, sexual problems, sexual health issues, FSD symptoms, and
sexual disability were used interchangeably with sexualREV 5.4.0 DTD  SXMR47_proodysfunction. Thus, it is clear that more standardization is needed
“so that professionals can better compare and evaluate the liter-
ature using a common argot.”10
Few publications in the present study assessed distress over
sexual problems (10 of 95 studies in the meta-analysis, 11 of
135 in the literature review). Experts have argued that sexually
related personal distress is a fundamental component of sexual
disorders.26,176 Indeed, several studies have shown that the
inclusion of personal distress yields lower prevalence rates of
FSD in population studies.23-25 Owing to the scarcity of
studies in this systematic review that assessed personal distress,
the authors could not account for this variable. Once again,
this illustrates the need for greater consistency and standardi-
zation in the assessment of sexual function in general
populations.
A potential reporting bias within the studies should be
mentioned. Several researchers indicated that the women in their
studies (particularly in conservative cultures) might have been
too shy to speak about sexual matters.63,105,125 This could have
resulted in an under-reporting of symptoms. Conversely, over-
reporting might have occurred in populations in which women
are more open and more interested in talking about their sexu-
ality.148 Social acceptability also can affect responses. For
example, in some Asian cultures, desiring sex as a woman is
associated with inﬁdelity.105 In contrast, in Western cultures,
sexual impulses are welcomed and the lack thereof is perceived as
a dysfunction.177Limitations of Systematic Review
The present systematic review provides an analysis of factors
that, based on previous systematic reviews, appeared to be
pertinent to prevalence rates. Further factor analyses and sub-
group classiﬁcations are certainly possible, yet these would exceed
the scope of this particular review.
There were three limitations of the present systematic re-
view. The literature search was limited to publications in
English, decreasing the number of studies that might have
been included. The present review also focused on women no
older than 49 years; a review that included older women could
have yielded different results, because sexual dysfunction has
been shown to be related to age.2 Because nearly all studies
were cross-sectional studies, it is not possible to draw con-
clusions as to the causal associations of the investigated factors
with sexual dysfunction.CONCLUSIONS
This systematic review of the literature (2000e2014) and
meta-analysis of 95 international studies showed that 41% of
premenopausal women report FSD. These ﬁndings coincide
with previous ﬁndings yet provide a far more robust estimate of
the prevalence of FSD and the individual sexual disorders,
while taking key factors of study design into account.Sex Med Rev 2016;-:1e16
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Female Sexual Dysfunction in Premenopausal Women 11Considering that two of ﬁve of premenopausal women report
some form of sexual dysfunction, all medical professionals need
to take an active role in addressing sexual dysfunction with
each patient across medical subspecialties. To corroborate these
ﬁndings, future research should focus on conducting longitu-
dinal studies with representative populations, comprehensive
assessment of relevant cofactors, and validated assessment tools
and cutoffs. Further studies are needed to understand better
sexual dysfunction in women living in conservative cultures,
women with bisexual and homosexual preferences, and
adolescents.Corresponding Author: Megan E. McCool, MPH, Epidemi-
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